All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.